Tag: Surveil DCB
Surmodics receives FDA approval for the SurVeil drug-coated balloon
Surmodics has announced the receipt of US Food and Drug Administration (FDA) approval for the SurVeil drug-coated balloon (DCB).
A company press release notes that...
SurVeil DCB demonstrates sustained durability of safety, efficacy endpoints in TRANSCEND
In the TRANSCEND clinical trial, the SurVeil drug-coated balloon (DCB; Surmodics) demonstrated "excellent efficacy and safety" out to 24-month follow-up. This is according to...
Lower-dose SurVeil DCB achieves non-inferiority with IN.PACT Admiral balloon
Kenneth Rosenfield (Boston, USA) speaks to Vascular News about the TRANSCEND trial, a non-inferiority randomised controlled trial, which looked to demonstrate safety and efficacy of the...
Surmodics completes enrolment in pivotal TRANSCEND clinical trial
Surmodics has completed enrolment in TRANSCEND, its pivotal clinical trial for the SurVeil drug-coated balloon (DCB).
“TRANSCEND is a rigorous level one, randomised controlled trial...
12-Month data from PREVEIL study of SurVeil DCB presented at VIVA
Data from the PREVEIL early feasibility study of the SurVeil drug-coated balloon (DCB, Surmodics) were shared in a late-breaking clinical trial presentation at the...
